Table of Contents Author Guidelines Submit a Manuscript
Pulmonary Medicine
Volume 2012, Article ID 610921, 6 pages
http://dx.doi.org/10.1155/2012/610921
Clinical Study

Effect of Nebulized Morphine on Dyspnea of Mustard Gas-Exposed Patients: A Double-Blind Randomized Clinical Trial Study

1Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Mollasadra Street, P.O. Box 19945-546, Tehran, Iran
2School of Medicine, Jahrom University of Medical Sciences, Jahrom 7414846199, Iran
3Department of Neurology, Shahid Beheshti University of Medical Sciences and Health Services, Tehran 19839-63113, Iran

Received 8 December 2011; Revised 20 January 2012; Accepted 20 January 2012

Academic Editor: Marc A. Judson

Copyright © 2012 Majid Shohrati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Elkington, P. White, J. Addington-Hall, R. Higgs, and P. Edmonds, “The healthcare needs of Chronic obstructive pulmonary disease patients in the last year of life,” Palliative Medicine, vol. 19, no. 6, pp. 485–491, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. B. Nicotra and R. Carter, “The use of opiates in chronic obstructive pulmonary disease,” Clinical Pulmonary Medicine, vol. 2, no. 3, pp. 143–151, 1995. View at Google Scholar · View at Scopus
  3. M. A. Johnson, A. A. Woodcock, and D. M. Geddes, “Dihydrocodeine for breathlessness in 'pink puffers',” British Medical Journal, vol. 286, no. 6366, pp. 675–677, 1983. View at Google Scholar · View at Scopus
  4. R. W. Light, J. R. Muro, R. I. Sato, D. W. Stansbury, C. E. Fischer, and S. E. Brown, “Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease,” American Review of Respiratory Disease, vol. 139, no. 1, pp. 126–133, 1989. View at Google Scholar · View at Scopus
  5. A. Tooms, A. McKenzie, and H. Grey, “Nebulised morphine [26],” Lancet, vol. 342, no. 8879, pp. 1123–1124, 1993. View at Google Scholar · View at Scopus
  6. M. Farncombe, S. Chater, and A. Gillin, “The use of nebulized opioids for breathlessness: a chart review,” Palliative Medicine, vol. 8, no. 4, pp. 306–312, 1994. View at Google Scholar · View at Scopus
  7. S. R. Mabe and J. F. Connelly, “Nebulized morphine for the relief of dyspnea,” American Journal of Health-System Pharmacy, vol. 52, no. 2, pp. 146–148, 1995. View at Google Scholar · View at Scopus
  8. D. E. Hilleman, P. A. Foral, M. A. Malesker, and G. Huerta, “Nebulized opioids use in COPD,” Chest, vol. 125, no. 2, pp. 691–694, 2004. View at Publisher · View at Google Scholar
  9. M. Farncombe and S. Chater, “Case studies outlining use of nebulized morphine for patients with end- stage chronic lung and cardiac disease,” Journal of Pain and Symptom Management, vol. 8, no. 4, pp. 221–225, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Eaton, J. Hall, and S. MacDonald, “Does nebulized morphine offer symptom relief to patients with disabling dyspnea during end-stage disease?” Canadian Family Physician, vol. 45, pp. 319–320, 1999. View at Google Scholar · View at Scopus
  11. M. Ghanei and A. A. Harandi, “Long term consequences from exposure to sulfur mustard: a review,” Inhalation Toxicology, vol. 19, no. 5, pp. 451–456, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ghanei, M. Mokhtari, M. M. Mohammad, and J. Aslani, “Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography,” European Journal of Radiology, vol. 52, no. 2, pp. 164–169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. United Nations Security Council, “Report of the specialist appointed by the secretary general to investigate allegation by the Islamic Republic of Iran concerning the use of chemical weapons,” Tech. Rep. 3/16433, United Nations Security Council, New York, NY, USA, 1986. View at Google Scholar
  14. S. Khateri, M. Ghanei, S. Keshavarz, M. Soroush, and D. Haines, “Incidence of Lung, Eye, and Skin Lesions as Late Complications in 34,000 Iranians with Wartime Exposure to Mustard Agent,” Journal of Occupational and Environmental Medicine, vol. 45, no. 11, pp. 1136–1143, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. R. Masood and S. H. L. Thomas, “Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects,” British Journal of Clinical Pharmacology, vol. 41, no. 3, pp. 250–252, 1996. View at Google Scholar · View at Scopus
  16. A. R. Masood, M. M. F. Subhan, J. W. Reed, and S. H. L. Thomas, “Effects of inhaled nebulized morphine on ventilation and breathlessness during exercise in healthy man,” Clinical Science, vol. 88, no. 4, pp. 447–452, 1995. View at Google Scholar · View at Scopus
  17. A. G. E. M. de Boer, J. J. B. Van Lanschot, P. F. M. Stalmeier et al., “Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?” Quality of Life Research, vol. 13, no. 2, pp. 311–320, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Farncombe, S. Chater, and A. Gillin, “The use of nebulized opioids for breathlessness: a chart review,” Palliative Medicine, vol. 8, no. 4, pp. 306–312, 1994. View at Google Scholar · View at Scopus
  19. P. C. Quelch, D. E. Faulkner, and J. W. S. Yun, “Nebulized opioids in the treatment of dyspnea,” Journal of Palliative Care, vol. 13, no. 3, pp. 48–52, 1997. View at Google Scholar · View at Scopus
  20. I. H. Young, E. D. A. Viskas, and V. A. Keena, “Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease,” Thorax, vol. 44, no. 5, pp. 387–390, 1989. View at Google Scholar · View at Scopus
  21. W. M. DiSalvo, M. M. Joyce, L. B. Tyson, A. E. Culkin, and K. Mackay, “Putting evidence into practice: evidence-based interventions for cancer-related dyspnea,” Clinical journal of oncology nursing, vol. 12, no. 2, pp. 341–352, 2008. View at Google Scholar · View at Scopus
  22. C. Quigley, S. Joel, N. Patel, A. Baksh, and M. Slevin, “A phase I/II study of nebulized morphine-6-glucuronide in patients with cancer-related breathlessness,” Journal of Pain and Symptom Management, vol. 23, no. 1, pp. 7–9, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Bruera, K. Macmillan, J. Pither, and R. N. MacDonald, “Effects of morphine on the dyspnea of terminal cancer patients,” Journal of Pain and Symptom Management, vol. 5, no. 6, pp. 341–344, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Baydur, “Nebulized morphine: a convenient and safe alternative to Dyspnea relief?” Chest, vol. 125, no. 2, pp. 363–365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Barber and R. Gottschlich, “Opioid agonists and antagonists: an evaluation of their peripheral actions in inflammation,” Medicinal Research Reviews, vol. 12, no. 5, pp. 525–562, 1992. View at Google Scholar · View at Scopus
  26. S. E. Zebraski, S. M. Kochenash, and R. B. Raffa, “Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea,” Life Sciences, vol. 66, no. 23, pp. 2221–2231, 2000. View at Google Scholar · View at Scopus
  27. P. J. Cabot, T. Cramond, and M. T. Smith, “Morphine has a dual concentration-dependent effect on K+-evoked substance P release from rat peripheral airways,” Pulmonary Pharmacology and Therapeutics, vol. 10, no. 4, pp. 215–221, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Sato, Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano, “In vivo evidence for the specific binding of human β-endorphin to the lung and liver of the rat,” Biochemical Pharmacology, vol. 37, no. 11, pp. 2273–2278, 1988. View at Publisher · View at Google Scholar · View at Scopus
  29. J. J. Adcock and T. W. Smith, “Inhibitory effects of the opioid peptide BW443C on smaller diameter sensory nerve activity in the vagus,” British Journal of Pharmacology, vol. 96, p. 596, 1987. View at Google Scholar
  30. D. R. Wissing, “Humidity and aerosol therapy,” in Mosby's Respiratory Care Equipment, J. M. Cairo and S. P. Pilbeam, Eds., pp. 90–137, Mosby, St. Louis, Mo, USA, 1999. View at Google Scholar
  31. W. Beauford, T. T. Saylor, D. W. Stansbury, K. Avalos, and R. W. Light, “Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient,” Chest, vol. 104, no. 1, pp. 175–178, 1993. View at Google Scholar · View at Scopus
  32. R. Leung, P. Hill, and J. Burdon, “Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease,” Thorax, vol. 51, no. 6, pp. 596–600, 1996. View at Google Scholar · View at Scopus
  33. R. C. Wilson and P. W. Jones, “A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise,” Clinical Science, vol. 76, no. 3, pp. 277–282, 1989. View at Google Scholar · View at Scopus
  34. A. R. Masood, J. W. Reed, and S. H. L. Thomas, “Lack of effect of inhaled morphine on exercise induced breathlessness in chronic obstructive pulmonary disease,” Thorax, vol. 50, no. 6, pp. 629–634, 1995. View at Google Scholar · View at Scopus
  35. “The effect of aerosolized morphine on exercise endurance and breathlessness in patients with advanced chronic lung disease,” American Review of Respiratory Disease, vol. 151, p. A548, 1995.
  36. C. Davis, C. Hodder, S. Love, R. Shah, M. Slevin, and J. Wedzicha, “Effect of nebulised morphine and morphine-6-glucuronide on exercise endurance in patients with chrochronic obstructive pulmonary disease,” Thorax, vol. 49, 393 pages, 1994. View at Google Scholar
  37. G. Zeppetella, “Nebulized morphine in the palliation of dyspnoea,” Palliative Medicine, vol. 11, no. 4, pp. 267–275, 1997. View at Google Scholar · View at Scopus
  38. A. L. Jennings, A. N. Davies, J. P. T. Higgins, J. S. R. Gibbs, and K. E. Broadley, “A systematic review of the use of opioids in the management of dyspnoea,” Thorax, vol. 57, no. 11, pp. 939–944, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. A. O. Harris-Eze, G. Sridhar, R. E. Clemens, T. A. Zintel, C. G. Gallagher, and D. D. Marciniuk, “Low-dose nebulized morphine does not improve exercise in interstitial lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 6, pp. 1940–1945, 1995. View at Google Scholar · View at Scopus
  40. J. Churbasik, H. Wust, G. Friedrich, and E. Geller, “Absorption and bioavailability of nebulized morphine,” British Journal of Anaesthesia, vol. 61, no. 2, pp. 228–230, 1988. View at Google Scholar · View at Scopus
  41. N. Sarhill, D. Walsh, E. Khawam, P. Tropiano, and M. K. Stahley, “Nebulized hydromorphone for dyspnea in hospice care of advanced cancer,” The American Journal Of Hospice And Palliative Care, vol. 17, no. 6, pp. 389–391, 2000. View at Google Scholar · View at Scopus
  42. C. L. Davis, W. Lam, and M. Butcher, “Low systemic bioavailability of nebulized morphine: potential therapeutic role for the relief of dyspnea,” in Proceedings of the Annual Meeting of the American Society of Clinical Oncology, vol. 11, p. A359, 1992.
  43. K. Tanaka, Y. Shima, R. Kakinuma et al., “Effect of nebulized morphine in cancer patients with dyspnea: a pilot study,” Japanese Journal of Clinical Oncology, vol. 29, no. 12, pp. 600–603, 1999. View at Google Scholar · View at Scopus
  44. M. McCaffery, “Pain control. Barriers to use of available information. World Health Organization Expert Committee on cancer pain relief and active supportive care,” Cancer, vol. 70, supplement 5, pp. 1438–1499, 1992. View at Google Scholar
  45. C. Davis, “The role of nebulised drugs in palliating respiratory symptoms of malignant disease,” The European Journal of Palliative Care, vol. 10, pp. 9–15, 1995. View at Google Scholar · View at Scopus
  46. R. H. Kallet, “The role of inhaled opioids and furosemide for the treatment of dyspnea,” Respiratory Care, vol. 52, no. 7, pp. 900–910, 2007. View at Google Scholar · View at Scopus
  47. B. Varkey, “Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients,” Current Opinion in Pulmonary Medicine, vol. 16, no. 2, pp. 150–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. R. D. Stark, A. C. Stark, and N. J. M. Russell, “Dyspnea: a possible target for pharmacological intervention,” in Respiratory Sensation: Lung Biology in Health and Disease, L. Adams and A. Guz, Eds., vol. 90, pp. 341–363, Marcel Dekker, New York, NY, USA, 1996. View at Google Scholar